P845 ATLAS 1: the first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections

G. Ralph Corey, Martín E. Stryjewski, W. O'Riordan, Vance G. Fowler, Douglas Patrick Ross, Alan R. Hopkins, M.M. Kitt, S L Barriere

International Journal of Antimicrobial Agents

March 1, 2007

10.1016/s0924-8579(07)70686-6

Cited by 4

Abstract

Related Papers

No related papers found

Powered by citation graph analysis